Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)
Date: 2023-13-02 Authors: Silverberg JI, Bissonnette R, Kircik L, Murrell DF, Selfridge A, Liu K, Ahluwalia G, Guttman-Yassky E Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Safety of baricitinib in patients with alopecia areata
Date: 2023-10-02 Authors: Bissonnette R Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
Date: 2023-09-02 Authors: Kim BS, Bissonnette R, Nograles K, Munera C, Shah N, Jebara A, Cirulli J, Goncalves J, Lebwohl M Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study
Date: 2023-08-02 Authors: Melissa L. Johnson, James Strauss, Manish R. Patel, Edward B. Garon, Keith D. Eaton, Tavette Neskorik, Josée Morin, Richard Chao, Balazs Halmos Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor ÎČ antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
Date: 2023-03-02 Authors: Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
Date: 2023-01-02 Authors: Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris L, Jones T, Saint-Cyr Proulx E, Bissonnette R, Bhatia N, Koppel R, Guenthner S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droege M, Berk D Category: Dermatitis (all types) Conflict of interest statement: Conflicts […]
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines
Date: 2023-01-01 Authors: Sara Mirali, Evan Tang, Aaron M Drucker, Irina Turchin, Melinda Gooderham, Nick Levell, Jennifer Beecker, Robert Bissonnette, Helen Catherall, Jo-Ann Lapointe McKenzie, Nicole Hawkins, Chih-Ho Hong, Sunil Kalia, Kim Papp, An-Wen Chan Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). […]
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
Date: 2022-13-12 Authors: Abuabara K, Eichenfield LF, Bissonnette R, Silverberg JI, Bagel J, Guttman-Yassky E, Thaci D, Simpson EL, Harris JE, Krueger J, Myers DE, Gamelli A, Milutinovic M, Parneix A, Crawford JM, Munoz B, Paller AS Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix […]
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
Date: 2022-02-12 Authors: Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L. Reckamp, Sunil Sharma, Hirak Der-Torossian, James G. Christensen, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Richard Chao & Geoffrey I. Shapiro Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 […]
Efficacy of downtitration or treatment withdrawal compared to continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomised substudy from the long-term extension study, BREEZE-AD3
Date: 2022-11-17 Authors: Kristian Reich, Eric Simpson, Andreas Wollenberg, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, Sherry Chen, Jonathan I Silverberg Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
